Loading…
Employees: 3,603
Size Zhejiang Int'l (000411.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $828M, the 2676th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.77 on 6 Nov 2026.
Performance Over six months the shares fell 7.8%, against -9.5% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 20 in its peer set.
Growth Revenue grew 3.4% over the last twelve months (peer median +1.8%); the operating margin is 2.5% (peer median 10.9%).
Valuation It trades at 0.3× enterprise value to sales against a peer median of 2.9× (cheapest of 19).
Capital Return on invested capital runs 1.9 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥34.7B | CN¥33.6B | CN¥33.3B | CN¥32.0B | CN¥30.6B |
| Revenue growth | — | +1% | +4% | +5% | — |
| Gross profit | CN¥2.58B | CN¥2.25B | CN¥2.23B | CN¥2.10B | CN¥1.88B |
| EBITDA | n/a | CN¥1.18B | CN¥1.12B | CN¥1.01B | CN¥921M |
| Net income | CN¥479M | CN¥501M | CN¥526M | CN¥489M | CN¥212M |
| Free cash flow | -CN¥483,610 | CN¥119M | CN¥130M | CN¥257M | CN¥284M |
| Capital expenditure | CN¥297M | CN¥237M | CN¥280M | CN¥168M | CN¥107M |
| Total debt | CN¥6.26B | CN¥5.88B | CN¥4.33B | CN¥3.52B | CN¥2.96B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000411.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.3% | -2.2% | 11th highest of 21 |
| 6-month return | -7.8% | -9.5% | 9th highest of 20 |
| Distance from 52-week high | -32.0% | -32.8% | 10th highest of 21 |
| Revenue growth (TTM) | +3.4% | +1.8% | 8th highest of 19 |
| Operating margin | 2.5% | 10.9% | 5th lowest of 19 |
| EV / Sales | 0.3× | 2.9× | cheapest of 19 |
| ROIC minus cost of capital | +1.9 pp | -1.7 pp | 8th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | 0.3× | n/a | n/a |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | 32.3× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | 3.2× | -1.8% | +2.6% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $835M | -28% | +23% | 36% | 8.1× | 17.1% | +22.7% |
| Latigo Biotherapeutics LTGO | United States | $835M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $839M | -36% | +3% | 18% | 1.2× | -10.5% | +1.9% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | 5.7× | 10.7% | -1.4% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 0.9× | n/a | n/a |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 1.9× | 4.8% | +22.5% |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |